Advertisement

Cardiac Resynchronization Therapy: The Low Voltage Road or the High Voltage Road?

  • G. Boriani
  • M. Biffi
  • C. Martignani
  • C. Camanini
  • C. Valzania
  • I. Diemberger
  • D. Saporito
  • P. Bartolini
  • A. Branzi
Conference paper

Abstract

Cardiac resynchronization therapy is an additional therapeutic option for heart failure patients that has became available in recent years and aroused great interest among both electrophysiologists and clinical cardiologists managing heart failure patients. The prevalence of conduction disturbances (QRS interval ≥120 ms) among patients with left ventricular dysfunction or overt heart failure has been found to range between 27% and 53% [1–3]. Upon analyzing subjects with varying degrees of functional impairment according to New York Heart Association (NYHA) functional class, wider mean QRS intervals were found in subjects with a higher degree of functional impairment [4]. In subjects with dilated cardiomyopathy the QRS interval was widened in elec- trograms recorded shortly before death as compared to recordings made a mean of 35 months before the terminal event [5]. In unselected patients, left bundle branch block was associated with increased risk of both total mortality and sudden death at 1 year [2]. In another study [6] a QRS duration >110 ms was associated with increased mortality independently of left ventricular ejection fraction. It is a matter for investigation to assess whether left bundle branch block with left QRS axis deviation is most closely related to left ventricular enlargement and left ventricular dysfunction or whether it carries additional prognostic implications [7]. In a recent paper [8], a widening of the QRS interval in patients with heart failure who were followed by a heart failure clinic was a definite and independent predictor of mortality. According to these data, analysis of the QRS interval may provide additional information as a basis for selecting candidates for nonpharmacological treatments.

Keywords

Cardiac Resynchronization Therapy Heart Failure Patient Implantable Cardioverter Defibrillator Left Bundle Branch Block Idiopathic Dilate Cardiomyopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aaronson KD, Schwartz JS, Chen TM et al (1997) Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95:2660–2667PubMedCrossRefGoogle Scholar
  2. 2.
    Baldasseroni S, Opasich C, Gorini M et al (2002) Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 143:398–405PubMedCrossRefGoogle Scholar
  3. 3.
    Shamim W, Francis DP, Yousufuddin M et al (1999) Intraventricular conduction delay: a prognostic marker in chronic heart failure. Int J Cardiol 70:171–178PubMedCrossRefGoogle Scholar
  4. 4.
    Stellbrink C, Auricchio A, Diem B et al (1999) Potential benefit of biventricular pacing in patients with congestive heart failure and ventricular tachyarrhythmia. Am J Cardiol 83:143D–150DPubMedCrossRefGoogle Scholar
  5. 5.
    Wilensky RL, Yudelman P, Cohen AI et al (1988) Serial electrocardiographic changes in idiopathic dilated cardiomyopathy confirmed at necropsy. Am J Cardiol 62:276–283PubMedCrossRefGoogle Scholar
  6. 6.
    Silvet H, Amin J, Padmanabhan S, Pai RG (2001) Prognostic implications of increased QRS duration in patients with moderate and severe left ventricular systolic dysfunction. Am J Cardiol 88:182–185, A6PubMedCrossRefGoogle Scholar
  7. 7.
    Das MK, Cheriparambil K, Bedi A et al (2001) Prolonged QRS duration (QRS ≥170 ms) and left axis deviation in the presence of left bundle branch block: a marker of poor left ventricular systolic function? Am Heart J 142:756–759PubMedCrossRefGoogle Scholar
  8. 8.
    Grigioni F, Carinci V, Boriani G et al (2002) Accelerated QRS widening as an independent predictor of cardiac death or of the need for heart transplantation in patients with congestive heart failure. J Heart Lung Transplant 21:899–902PubMedCrossRefGoogle Scholar
  9. 9.
    Abraham WT, Fisher WG, Smith AL et al (2002) Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845–1853PubMedCrossRefGoogle Scholar
  10. 10.
    Braunschweig F, Linde C, Gadler F et al (2000) Reduction of hospital days by biventri-cular pacing. Eur J Heart Fail 2:399–406PubMedCrossRefGoogle Scholar
  11. 11.
    Yu CM, Chau E, Sanderson JE, Fan K et al (2002) Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation 105:438–445PubMedCrossRefGoogle Scholar
  12. 12.
    Cleland IG, Thackray S, Goodge L et al (2002) Outcome studies with device therapy in patients with heart failure. J Cardiovasc Electrophysiol 13:S73-91Google Scholar
  13. 13.
    Bansch D, Antz M, Boczor S et al (2002) Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 105:1453–1458PubMedCrossRefGoogle Scholar
  14. 14.
    The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators (1997) A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337:1576–1583CrossRefGoogle Scholar
  15. 15.
    Connolly SJ, Gent M, Roberts RS et al (2000) Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amio-darone. Circulation 101:1297–1302PubMedCrossRefGoogle Scholar
  16. 16.
    Connolly SJ, Hallstrom AP, Cappato R et al (2000) Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 21:2071–2078Google Scholar
  17. 17.
    Ezekowitz JA, Armstrong PW, McAlister FA (2003) Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med 138:445–452PubMedGoogle Scholar
  18. 18.
    Moss AJ, Hall WJ, Cannom DS et al (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335:1933–1940Google Scholar
  19. 19.
    Moss AJ, Zareba W, Hall WJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883PubMedCrossRefGoogle Scholar
  20. 20.
    Domanski MJ, Sakseena S, Epstein AE et al (1999) Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable efibrillators. J Am Coll Cardiol 34:1090–1095PubMedCrossRefGoogle Scholar
  21. 21.
    Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) (1999) Effect of metoprolol CR/XL in chronic heart failure. Lancet 353:2001–2007CrossRefGoogle Scholar
  22. 22.
    Higgins SL, Yong P, Sheck D et al (2000) Biventricular pacing diminishes the need for implantable cardioverter defibrillator therapy. Ventak CHF Investigators. J Am Coll Cardiol 36:824–827CrossRefGoogle Scholar
  23. 23.
    Bristow M (2003) Cardiac resynchronization therapy reduces hospitalizations, and cardiac resynchronization therapy and implantable defibrillator reduce mortality in chronic heart failure. Results of the COMPANION trial. Late breaking clinical trials. American College of Cardiology 52nd Annual Scientific SessionGoogle Scholar
  24. 24.
    Strickberger SA (2000) Multicenter randomized trial comparing amiodarone to implantable defibrillator in patients with nonischemic cardiomyopathy and asymptomatic nonsustained ventricular tachycardia: AMIOVIRT Trial. Circulation 102:2784CrossRefGoogle Scholar
  25. 25.
    Grimm W, Hoffmann JJ, Muller HH et al (2002) Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol 39:780–787PubMedCrossRefGoogle Scholar
  26. 26.
    Cohn JN (1990) Mechanisms in heart failure and the role of angiotensin-converting enzyme inhibition. Am J Cardiol 66:2D–6DPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2004

Authors and Affiliations

  • G. Boriani
    • 1
  • M. Biffi
    • 1
  • C. Martignani
    • 1
  • C. Camanini
    • 1
  • C. Valzania
    • 1
  • I. Diemberger
    • 1
  • D. Saporito
    • 1
  • P. Bartolini
    • 2
  • A. Branzi
    • 1
  1. 1.Istituto di CardiologiaUniversità di BolognaBolognaItaly
  2. 2.Laboratorio di Ingegneria BiomedicaIstituto Superiore di SanitàRomeItaly

Personalised recommendations